Fuchsia

Fuchsia (Fuchsia spp.): A Botanical, Ethnopharmacological, and Phytochemical Reference

1. Identity and Taxonomy

1.1 Botanical and Systematic Classification

Fuchsia is a genus of flowering plants that consists mostly of shrubs or small trees; almost 110 species are recognized, the vast majority native to South America, with a few occurring north through Central America to Mexico, and several from New Zealand to Tahiti. Today, 108 species representing 122 taxa of the genus Fuchsia are scientifically recognized and organized into twelve sections based on shared characteristics.

The genus Fuchsia is part of the family Onagraceae and includes many sections and endemic species. Fuchsia is a member of the Onagraceae (the Evening Primrose or Willowherb family), which also includes popular garden plants such as evening primroses (Oenothera). One species, F. magellanica, extends as far as the southern tip of South America, occurring on Tierra del Fuego in the cool temperate zone, but the majority are tropical or subtropical.

The species most frequently cited in the medicinal and supplemental literature include:

• Fuchsia magellanica Lam. — a native plant of the Andean-Patagonian region, also naturalized in Argentina and other parts of the world. Known in Mapuche tradition as chilco or chillcoagu.
• Fuchsia triphylla L. — the first Fuchsia species to be scientifically described, discovered on the Caribbean island of Hispaniola about 1696–1697 by the French Minim friar and botanist Charles Plumier during his third expedition to the Greater Antilles.
• Fuchsia standishii J. Harrison — a species widely used in traditional medicine in southern Ecuador for treating various ailments, including high blood pressure, as an antacid and a relaxant.

1.2 Nomenclature and History of the Name

The first species to be scientifically described, Fuchsia triphylla, was discovered on the Caribbean island of Hispaniola about 1696–1697 by Charles Plumier, who named the new genus after German botanist Leonhart Fuchs (1501–1566). In his 1703 publication Nova Plantarum Americanarum Genera, he named the new genus Fuchsia triphylla flore coccineo, honoring the 16th-century German botanist and physician Leonhart Fuchs for his contributions to herbal illustrations and botany. This ambiguity persisted until the Linnaean era, when Carl Linnaeus incorporated the genus into his binomial nomenclature system; in the first edition of Species Plantarum (1753), Linnaeus listed Fuchsia triphylla as a species within the genus, simplifying Plumier's lengthy polynomial name and establishing a clear taxonomic foundation.

Leonhart Fuchs, the namesake of the genus, was born in 1501 in Wemding in the Duchy of Bavaria; a physician and professor, he occupied the chair of Medicine at the University of Tübingen from his appointment at the age of 34 until his death in 1566. In the course of his career, Fuchs wrote the seminal De Historia Stirpium Commentarii Insignes, richly illustrated and published in 1542; along with Otto Brunfels and Hieronymus Bock, he is today considered one of the three fathers of botany.

1.3 Common Names and Natural Geographic Range

In the mountainous regions of Chile and Argentina, F. magellanica is called chilco by the indigenous Mapuche people. Other common names include aljaba (Argentina), "hardy fuchsia," and "lady's eardrops." Fuchsia standishii is a flowering plant species native to South America and New Zealand, belonging to the Onagraceae family. F. magellanica occurs in temperate southern regions of Argentina and Chile, from latitude 32°50′S to the Straits of Magellan.

1.4 Common Forms and Preparations as a Natural Ingredient

The best form to take advantage of the medicinal properties of fuchsia is through herbal remedies; these preparations can be made from the roots, stalks, leaves, flowers, and berries of the fuchsia plant — some taken orally and others for external use only. Documented preparation forms include:

• Infusions and teas: Dried petals or leaves steeped in hot water. A petal infusion (tea) uses 1–2 g dried petals per 250 ml hot water, up to 1–2 cups per day as part of a varied diet.
• Tinctures (ethanolic extracts): Used in laboratory and traditional settings; tinctures of leaves and flowers have been the primary extract type studied scientifically.
• Fresh berries and culinary use: Fuchsia berries vary in flavor, from very bitter to pleasant and sweet, and can be consumed raw or cooked; it is generally thought that the darker the berry, the sweeter its flavor. Fresh berries in recipes: 20–50 g (a small handful) folded into fruit salads, syrups, or jam blends.
• Poultices and topical preparations: Ethnobotanical notes describe traditional topical use of fresh leaves and poultices for minor skin complaints.
• Decoctions: Leaves taken internally as a decoction or infusion were used to treat an array of ailments including kidney and bladder conditions, infant fevers, and externally as a wash on sprained limbs.

It is important to differentiate fuchsia-as-food from fuchsia-as-supplement: there is no widely accepted standardized extract, no consensus therapeutic dose, and no regulatory monograph comparable to better-studied botanicals.

2. Traditional and Historical Use

2.1 Indigenous South American Traditions

Fuchsia magellanica, first eaten in Chile and Argentina by the Mapuche, Puelche, Tehuelche, and other native peoples, was consumed throughout its natural range. Fuchsia magellanica Lam., a shrub native to Chile, is widely used in traditional Mapuche medicine as a diuretic, emmenagogue, and wound healer.

F. magellanica (Onagraceae) is a native plant of the Andean-Patagonian region; leaves are used for treating indigestion, stomachache, as a sedative, for difficult delivery, and as an antiemmenagogue. In Mapuche nomenclature, the plant is documented under the names chilco and chillcoagu. It is a plant of importance for different communities of the Mapuche.

It has been used in traditional remedies as a diuretic and antipyretic. A 1994 study in Phytotherapy Research examined the hypotensive and diuretic effect of Fuchsia magellanica, alongside Equisetum bogotense, reflecting an earlier pharmacological interest in the plant's traditional indications.

In the Andean-Patagonian tradition, the plant's berries were also used as food. In the suburban forests of Austrocedrus chilensis in Bariloche, Argentina, the fruits of F. magellanica are used as food, being the only species of the Onagraceae family reported as an edible food source in that context.

2.2 Ecuadorian Traditional Use (Fuchsia standishii)

Fuchsia standishii J. Harrison is a species widely used in traditional medicine in southern Ecuador for treating various ailments, including high blood pressure, as an antacid, and as a relaxant. In studies by Rios et al. (2017), F. standishii emerges as a crucial component in the formulation of horchata, a beverage widely integrated into the traditional practices of southern Ecuador due to its recognized anti-inflammatory, analgesic, and diuretic properties.

2.3 Indigenous Uses in California (California Fuchsia, Epilobium canum)

A related plant known colloquially as "California fuchsia," now formally named Epilobium canum, was used by California Indigenous Peoples. California Indigenous Peoples employ fuchsia for a variety of medicinal uses; leaves taken internally as a decoction or infusion treat an array of ailments including kidney and bladder conditions, tuberculosis, infant fevers, and vomiting blood, and externally as a wash on sprained limbs. The leaves in a dried or powdered form applied topically treat cuts, wounds, sores on humans and livestock, and poison oak. The formal name for California fuchsia, Epilobium canum, is of relatively recent vintage (1992). It is noted here for ethnobotanical completeness, though it is a distinct species from the genus Fuchsia proper.

2.4 Romanian and European Ethnomedicine

Fuchsia magellanica and Fuchsia triphylla (hardy fuchsia and lady's eardrops, Onagraceae) are perennial cultivated plants all over Europe; in addition, F. magellanica is locally naturalized in the Azores, Ireland, and Britain; fresh leaves of several Fuchsia varieties are ethnomedicinally applied on wounds, furuncles, and skin inflammation as a fomentation.

2.5 Culinary and Food Use Across Cultures

In modern gardening and "edible flowers" cuisine, fuchsia is increasingly used because the entire experience — color, shape, and mild flavor — adds value to plates and drinks without overwhelming other ingredients. There is a range of recipes available using the different parts of the fuchsia plant; fuchsia berries vary in flavor from very bitter to pleasant and sweet, and can be consumed raw or cooked. They can be frozen and used when desired to make jams, jellies, and fruit chutneys; also, they can be added to cakes, muffins, brownies, and other dessert recipes.

The French monk and botanist Charles Plumier discovered fuchsia in the late 1600s; it was apparent to the natives at the time that there was no fuchsia plant toxicity, and Plumier wrote a great deal on the flavor and medicinal uses of the plant.

3. Key Constituents and Active Compounds

3.1 Anthocyanins

Laboratory research into fuchsia leaves and pigments has led to the isolation and characterization of phenolic compounds, including anthocyanins (the same family that colors blueberries and blackcurrants); these compounds are responsible for the vivid magentas and purples of the corolla and berry skins.

A 2011 phytochemical study published in Natural Product Communications (PubMed ID 21366041) is the most comprehensive characterization of fuchsia flower anthocyanins. Flowers of Fuchsia arborescens, F. boliviana, F. fulgens var. 'Variegata', F. magellanica, and twenty-nine F. magellanica cultivars contained some of thirteen anthocyanidin 3,5-diglucosides, 3-monoglycosides, and 3-(2″-galloylglucosides) altogether identified; peonidin 3-O-(2″-O-galloyl-β-glucopyranoside), not previously reported, was found in F. magellanica and F. fulgens var. 'Variegata'. The various corollas with purple nuances were correlated with a relatively high content of malvidin 3,5-diglucoside; flower colors were to a large extent correlated with the number of oxygen substituents on the anthocyanidin B-ring of the major anthocyanins.

A 1977 earlier study in Phytochemistry had established that 3-glucosides and 3,5-diglucosides of pelargonidin, cyanidin, peonidin, delphinidin, petunidin, and malvidin have been identified as flower pigments in the genus.

More recently, the leaves of F. magellanica and F. triphylla were found to contain several anthocyanins, such as cyanidin and peonidin derivatives.

3.2 Flavonoids

The presence of flavonoids in F. magellanica was confirmed by TLC, including quercetin, isoquercetin, hyperoside, and kaempferol; some of them — quercetin, hyperoside, and other glycosylated phenolic compounds — were identified by HPLC. Previous studies using plant material from outside Chile have confirmed its chemical composition — including flavonoids like quercetin and kaempferol in the leaves and various anthocyanins in the flowers.

3.3 Phenolic Acids and Other Polyphenols

From leaves of F. magellanica, researchers reported the presence of anthocyanins (cyanidin and peonidin), flavonoids (quercetin, kaempferol, and its galloyl-glycosides), as well as caffeic and gallic acid derivatives. A comprehensive LC-DAD-ESI-MS/MS study of F. magellanica and F. triphylla leaf extracts found that eighty-two gallic acid derivatives, hydroxycinnamic acid derivatives, and flavonoid glycosides were detected altogether in the samples; moreover, eight anthocyanins were described in the Fuchsia samples.

3.4 Summary of Phytochemical Profile by Plant Part

• Flowers: Rich in anthocyanins (cyanidin, peonidin, delphinidin, malvidin, petunidin, pelargonidin derivatives, including 3-glucosides, 3,5-diglucosides, and galloyl-glucosides).
• Leaves: Dominant in flavonoids (quercetin, kaempferol, isoquercetin, hyperoside) and phenolic acids (gallic acid, caffeic acid derivatives).
• Berries: Contain anthocyanins and are reported to contain vitamin C, though formal quantitative data from peer-reviewed literature on specific nutrient amounts is limited.

4. Scientific Evidence by Area of Use

4.1 Antispasmodic and Gastrointestinal Effects

Evidence level: Preclinical (animal/ex vivo) only. No human clinical trials.

The most rigorously conducted pharmacological study on Fuchsia to date was published in Phytomedicine Plus (2021), authored by Bernal Ochoa et al. This work evaluated the gastrointestinal, uterine, and sedative effects of leaves and flowers tinctures of F. magellanica from wild Patagonian and naturalized plants, as well as the mechanism of action and the flavonoids profile of both plants.

The ex-vivo effects were evaluated on contractile concentration-response curves of carbachol (CCh) and calcium (Ca²⁺) in rat isolated intestinal and uterine tissues. Results showed that leaves and flowers ethanolic extracts from both wild and cultivated F. magellanica showed intestinal and uterine antispasmodic effects, mainly by interfering with Ca²⁺ influx; in mice, the ethanolic extracts reduced intestinal transit and showed a sedative effect; the effects agree with the presence of flavonoids such as quercetin and kaempferol. The authors described this as the first study which gives experimental support for some of the traditional uses of F. magellanica.

The proposed mechanism centers on interference with calcium influx in smooth muscle. Some flavonoids were reported as responsible for antispasmodic effects in intestinal and uterine smooth muscles. These findings are limited by the fact that they are derived from isolated tissue and animal models and have not been validated in human subjects.

4.2 Sedative Effects

Evidence level: Preclinical (animal/in vivo) only. No human clinical trials.

In the same 2021 Bernal Ochoa et al. study, the extract also inhibited serotonin contractile concentration-response curves; although extracts did not show anxiolytic effect in the elevated cross plus-maze test, they reduced the spontaneous activity of mice in the open-field at 32.7 mg/kg T-L-Fm-P and 41.7 mg/kg T-L-Fm-BA. These doses are reported in terms of animal experimental concentrations and cannot be directly extrapolated to human use.

4.3 Antioxidant Activity

Evidence level: In vitro laboratory studies only. No human clinical trials.

A 2020 study published in Antioxidants (PMC7070992) examined phenolic extracts from F. magellanica and F. triphylla leaves using validated chemical and cell-based assays. The ethanolic extract exhibited the highest total phenolic (41.9 ± 0.2 µg GAE/mg), flavonoid (22.48 ± 0.03 µg QE/mg), and tannin (15.33 ± 0.03 µg CE/mg) contents, and showed strong antioxidant activity (DPPH IC₅₀ = 0.08 mg/mL; FRAP). Fuchsia species showed the strongest cytotoxicity and the highest antioxidant and antimicrobial activity among the plants tested in that comparison.

Previous studies demonstrated that ethanolic and aqueous extracts from F. magellanica and F. triphylla inhibit intracellular ROS production in 3T3 and HaCaT cells; ROS formation was experimentally induced by exposing the fibroblast and keratinocyte cells to peroxyl radicals from AAPH. These are cell-based assays and do not constitute clinical evidence of antioxidant benefit in humans.

4.4 Antimicrobial Activity

Evidence level: In vitro (microdilution assay) only. No human clinical trials.

Fuchsia species were studied using LC-MS/MS alongside other plants from Romanian ethnomedicine; antimicrobial activities were estimated using a standard microdilution method. Fuchsia species showed the strongest cytotoxicity and the highest antioxidant and antimicrobial activity in the panel studied. The specific organisms tested and MIC values are not reproduced here without access to the full data tables, but the authors attributed activity to the polyphenol content of leaf extracts.

4.5 Wound Healing and Cell Migration

Evidence level: In vitro (cell-based assay) only. No human clinical trials.

The 2020 PMC study examined wound healing-relevant parameters. Ethanolic extracts of Fuchsia species facilitated cell migration, most probably due to their various phenolic acid, flavonoid, and anthocyanin derivatives. The authors noted that their data might serve as a basis for further animal experiments to explore the complex action of Fuchsia species in wound healing assays. The main proposed mechanisms of the active constituents of leaf extracts in favor of wound healing are protection against microbial infection from the external environment, scavenging of free radicals with antioxidant effects, and enhancing of cell migration, proliferation, angiogenesis, and collagen production in the wounded area. All of these findings are in vitro and require animal and then clinical validation.

4.6 Antiproliferative and Potential Anticancer Activity

Evidence level: In vitro (cell line) only. No animal or human studies. Findings should not be interpreted as evidence of anticancer benefit.

A 2025 study (published in Plants, PMC12736804) explored the bioactive potential of polar extracts from the aerial parts of F. standishii, focusing on antiproliferative activity against a panel of human tumor cell lines (A549, HBL-100, HeLa, SW1573, T-47D). The plant material was sequentially extracted and partitioned into nine fractions; all fractions were screened for antiproliferative activity, and the most active fractions were further evaluated for their mechanism of cell death (apoptosis/necrosis), genotoxicity, and induction of oxidative stress. F. standishii extracts showed potent antiproliferative activity; the dichloromethane fraction (MW_D) was the most active (GI₅₀ range: 8.5–39 µg/mL), demonstrating the ability to induce apoptosis in tumor cells and cause genotoxic damage linked to oxidative stress.

In vitro studies have demonstrated pharmacological potential in F. magellanica, showing cytotoxic effects on fibroblast (3T3) and keratinocyte (HaCaT) cell lines, and significant inhibition of cell proliferation in human breast cancer cell cultures (MCF7 and MDA-MB-231). These are all in vitro findings. Translating cell or test-tube results into clinical benefits requires careful dosing, bioavailability data, and randomized trials — none of which are established for fuchsia.

4.7 Hypotensive and Diuretic Activity

Evidence level: Limited preclinical; one early pharmacological study in animal models. No robust human trials.

A 1994 study published in Phytotherapy Research examined the hypotensive and diuretic effect of Fuchsia magellanica alongside Equisetum bogotense. Thirty-five plant samples belonging to 30 Mapuche medicinal plants were assayed for xanthine oxidase and β-glucuronidase inhibitory activity as well as for brine shrimp toxicity and hypotensive effect in normotensive rats; a high number of extracts displayed significant inhibition towards the enzyme β-glucuronidase or elicited a hypotensive response. This study provides early biological plausibility for the traditional diuretic and hypotensive claims but does not constitute human clinical evidence.

5. Body Systems and Health Areas of Association

Based on the aggregated ethnopharmacological records and preclinical research identified in peer-reviewed sources, Fuchsia has been associated with the following body systems and health domains:

• Gastrointestinal System: Leaves are traditionally used for treating indigestion, stomachache, as a sedative, for difficult delivery, and as an antiemmenagogue. Preclinical antispasmodic effects have been demonstrated in rat intestinal tissue.
• Renal / Urinary System: F. magellanica is widely used in traditional Mapuche medicine as a diuretic, and early pharmacological work in normotensive rats provides limited support for this use.
• Reproductive System (uterine): Ethanolic extracts showed uterine antispasmodic effects, mainly by interfering with Ca²⁺ influx. Traditional use for difficult delivery and as an antiemmenagogue is documented.
• Central Nervous System (sedation): Ethanolic extracts of F. magellanica reduced spontaneous activity in mice in the open-field test at specific doses, indicating sedative potential — preclinical only.
• Integumentary System (skin): Ethnobotanical notes describe traditional topical use of fresh leaves and poultices for minor skin complaints. In vitro, extracts facilitated cell migration in fibroblast and keratinocyte models.
• Cardiovascular System: It has been used in traditional remedies as an antipyretic and diuretic with limited preclinical evidence for hypotensive activity in normotensive rats.
• Antioxidant / Cellular Protection: Well-characterized antioxidant activity in vitro, with high phenolic and flavonoid content driving free-radical scavenging properties.

6. Dosage Forms and Dosages Reported in Studies

There is no evidence-based "therapeutic dose" for fuchsia, and no authoritative monograph sets a medicinal range. The following figures are reported in the scientific or observational literature and are not recommendations:

• Petal infusion (tea): 1–2 g dried petals per 250 ml hot water, up to 1–2 cups per day, as part of a varied diet.
• Fresh berries (culinary): 20–50 g (a small handful) folded into fruit salads, syrups, or jam blends.
• In vivo sedative study (mice): Extracts reduced spontaneous activity of mice in the open-field at 32.7 mg/kg (T-L-Fm-P) and 41.7 mg/kg (T-L-Fm-BA). These are experimental animal doses and cannot be extrapolated to human use.
• Antiproliferative fractions (in vitro): The dichloromethane fraction of F. standishii was the most active at a GI₅₀ range of 8.5–39 µg/mL. This is a cell-culture concentration, not a therapeutic dose.

There is no widely accepted standardized extract, no consensus therapeutic dose, and no regulatory monograph comparable to better-studied botanicals. No European Medicines Agency (EMA), WHO, ESCOP, or German Commission E monograph has been established for any Fuchsia species as a medicinal product.

7. Safety Considerations and Interactions

7.1 General Edibility and Absence of Known Toxicity

All fuchsia fruit is edible and you can eat the flowers too; the berries are not toxic and can be eaten in a variety of ways; since there is no fuchsia plant toxicity established, it is safe to gather some berries and/or flowers and try them out. This represents consensus in horticultural and edible-plant literature, though formal toxicological studies specific to Fuchsia species are limited.

7.2 Genotoxicity — a Significant Preclinical Concern

The 2025 Plants study on F. standishii identified a notable safety signal in vitro: the dichloromethane fraction demonstrated the ability to induce apoptosis in tumor cells and cause genotoxic damage linked to oxidative stress. This genotoxic potential was observed at the extract concentrations tested in cell lines, not in whole-food culinary amounts. This finding underscores the importance of not extrapolating in vitro extract data to safety conclusions for food use or supplement formulation without further study.

7.3 Pesticide-Treated Ornamental Plants

Only plants grown for food should be consumed; avoid pesticide-treated ornamentals and wash gently before use. The vast majority of Fuchsia plants sold in garden centers are cultivated for ornamental purposes and may have been treated with systemic pesticides not suitable for consumption.

7.4 Pregnancy and Breastfeeding

There is not enough data on concentrated fuchsia preparations regarding pregnancy and breastfeeding. The traditional use of F. magellanica as an antiemmenagogue and for "difficult delivery" (an indication that implies uterine activity) is consistent with the demonstrated uterine antispasmodic and smooth muscle effects shown in the 2021 Bernal Ochoa et al. study, making high-dose or concentrated preparations a consideration of concern during pregnancy.

7.5 Immunocompromised Individuals

Immunocompromised individuals and people with poorly controlled diabetes should be aware that raw edible flowers can carry higher microbial loads than cooked foods.

7.6 Absence of Drug Interaction Data

No peer-reviewed clinical studies have examined drug interactions with any Fuchsia species preparation. Given that the predominant active constituents are quercetin, kaempferol, and related flavonoids — known, in other contexts, to influence cytochrome P450 enzyme activity — interactions are plausible in concentrated extract form, but no specific fuchsia-drug interaction data exists in the published scientific literature reviewed here.

7.7 Evidence Gap: No Human Clinical Trials

There are no controlled human trials showing that eating fuchsia flowers or berries improves specific health outcomes (skin healing, immunity, metabolic markers, or cardiovascular health). Polyphenols do contribute to dietary quality, but effects are context-dependent and often modest when foods are eaten in normal amounts; translating cell or test-tube results into clinical benefits requires careful dosing, bioavailability data, and randomized trials — none of which are established for fuchsia. The overall evidence base, as of 2025–2026, remains limited to in vitro cell studies, ex vivo tissue preparations, and animal model experiments, without any published Phase I/II human safety or efficacy trials.

References

• Bernal Ochoa et al. (2021). Intestinal/uterine antispasmodics, sedative effects of Fuchsia magellanica Lam. leaves' and flowers' extracts and their flavonolic components. Phytomedicine Plus. ScienceDirect.
• Csepregi et al. (2020). Cytotoxic, Antimicrobial, Antioxidant Properties and Effects on Cell Migration of Phenolic Compounds of Selected Transylvanian Medicinal Plants. Antioxidants. PMC7070992.
• Ramírez et al. (2025). Antiproliferative Effects of Polar Extracts of the Aerial Parts of Fuchsia standishii J. Harrison. Plants. PMC12736804.
• Jordheim et al. (2011). Anthocyanins from Fuchsia flowers. Natural Product Communications. PubMed 21366041.
• Ishikura & Sugahara (1977). Anthocyanins of Fuchsia (Onagraceae). Phytochemistry. ScienceDirect.
• Schmeda-Hirschmann et al. (1992). Hypotensive effect and enzyme inhibition activity of Mapuche medicinal plant extracts. Phytotherapy Research. Wiley Online Library.
• Universidad de Chile Repository. Caracterización química y evaluación de la capacidad antioxidante y antiinflamatoria in vitro de los extractos etanólicos de hojas y flores de Fuchsia magellanica Lam.
• CONICET Digital Repository. Bernal Ochoa et al. (2021). Intestinal/uterine antispasmodics, sedative effects of Fuchsia magellanica.
• PMC11459746. The complete chloroplast genome of Fuchsia standishii J. Harrison, 1840 (Onagraceae) from Yunnan, China.
• VitaLibrary (2025). Fuchsia: Properties, Uses, Dosage, and Side Effects.
• Wikipedia. Fuchsia (genus). Botanical overview and history.
• Wikipedia. Fuchsia magellanica. Distribution and traditional use.
• Sausal Creek Watershed Alliance. From the Potting Bench: California Fuchsia (Epilobium canum).
• HerbaZest. Fuchsia — medicinal herbs overview.
• Fuchsietum. Eat Your Fuchsias! Recipes and more.
• Gardening Know How. Are Fuchsias Edible: Learn About Eating Fuchsia Berries and Flowers.
• Pépinière Delhommeau. Fuchsia Information: History, Botany & Nomenclature.
• Wellcome Collection. Fuchsia magellanica Lam. Onagraceae — botanical and ethnobotanical record.